ArticleCureus2025
Evaluation of Changes in Optical Coherence Tomography (OCT) Biomarkers After Oral Eplerenone Therapy in Chronic Central Serous Chorioretinopathy and Their Correlation to Functional Visual Outcome.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to assess the efficacy of the mineralocorticoid receptor antagonist eplerenone on chronic central serous chorioretinopathy.
methodsIn this prospective observational study, patients diagnosed with chronic central serous chorioretinopathy fulfilling the inclusion criteria and exclusion criteria were recruited. The best-corrected visual acuity (BCVA) on baseline was noticed, and optical coherence tomography (OCT) parameters (central macular thickness (CMT), subfoveal choroidal thickness (SFCT), subretinal fluid (SRF) height and base, ellipsoid zone (EZ) integrity) were measured at baseline. Participants were then advised about starting the eplerenone 25 mg tablet, and after one month, if serum K+ is <5 mmol/L, the dose was increased to 50 mg for two months. The same variables were assessed after three months.
resultsIn this study, BCVA, SFCT, and SRF base changes from baseline to three months were statistically insignificant (p=0.061; p=0.354; p=0.577). However, CMT (p=0.016) and SRF height (p<0.001) have reduced significantly from baseline to three months. EZ integrity (p=0.009) showed significant changes from baseline to three months. On correlating BCVA changes with OCT parameters, findings were insignificant, but had a negative correlation for CMT (r=-0.030), SRF height (r=-0.083), and SRF base (r=-0.246).
conclusionDespite insignificant changes in BCVA, SFCT, SRF base, and EZ integrity, eplerenone showed a significant effect in reducing CMT and SRF height, which contributes to minimal improvement in visual acuity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.